

# Robert M Grant

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2802593/publications.pdf>

Version: 2024-02-01

225  
papers

23,671  
citations

13068

68  
h-index

8138

148  
g-index

225  
all docs

225  
docs citations

225  
times ranked

12040  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Combining information to estimate adherence in studies of pre-exposure prophylaxis for HIV prevention: Application to HPTN 067. <i>Statistics in Medicine</i> , 2022, , .   | 0.8 | 0         |
| 2  | Characterizing HIV-Preventive, Plasma Tenofovir Concentrationsâ€”A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials. <i>Clinical Infectious Diseases</i> , 2022, 75, 1873-1882.   | 2.9 | 10        |
| 3  | Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2117-e2123.  | 2.9 | 33        |
| 4  | Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2021, 72, 2025-2028.   | 2.9 | 4         |
| 5  | Non-B variants of HIV-1 in San Francisco, California. <i>Infection, Genetics and Evolution</i> , 2021, 90, 104677.  | 1.0 | 0         |
| 6  | Brief Report: Seroadaptive Behaviors Varied Among Geographically Diverse iPrEx Participants. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, e43-e47.   | 0.9 | 2         |
| 7  | Letter to the Editor: Revisiting the Pharmacological Forgiveness of HIV Pre-Exposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 407-408.  | 0.5 | 1         |
| 8  | Uptake, Retention, and Adherence to Pre-exposure Prophylaxis (PrEP) in TRIUMPH: A Peer-Led PrEP Demonstration Project for Transgender Communities in Oakland and Sacramento, California. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, S27-S38.                       | 0.9 | 24        |
| 9  | Facilitators and barriers affecting PrEP adherence among Thai men who have sex with men (MSM) in the HPTN 067/ADAPT Study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 249-254.  | 0.6 | 25        |
| 10 | Predicted Effectiveness of Daily and Nondaily Preexposure Prophylaxis for Men Who Have Sex With Men Based on Sex and Pill-taking Patterns From the Human Immuno Virus Prevention Trials Network 067/ADAPT Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 249-255.                         | 2.9 | 7         |
| 11 | HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health. <i>Aids</i> , 2020, 34, 699-706.  | 1.0 | 12        |
| 12 | Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2020, 396, 239-254. | 6.3 | 245       |
| 13 | Brief Report: High Accuracy of a Real-Time Urine Antibody-Based Tenofovir Point-of-Care Test Compared With Laboratory-Based ELISA in Diverse Populations. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 149-152.  | 0.9 | 11        |
| 14 | â€œA Good Habitâ€” Telehealth PrEP Users Find Benefit in Quarterly Monitoring Requirements. <i>Journal of the International Association of Providers of AIDS Care</i> , 2020, 19, 232595822091926.  | 0.6 | 12        |
| 15 | Community pharmacy delivered PrEP to STOP HIV transmission: An opportunity NOT to miss!. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, e18-e24.   | 0.7 | 13        |
| 16 | The Effect of Depression on Adherence to HIV Pre-exposure Prophylaxis Among High-Risk South African Women in HPTN 067/ADAPT. <i>AIDS and Behavior</i> , 2020, 24, 2178-2187.  | 1.4 | 13        |
| 17 | Identification of hepatitis B virus genotype I in Thailand. <i>Journal of Medical Virology</i> , 2019, 91, 717-721.   | 2.5 | 4         |
| 18 | Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 788-793.  | 0.5 | 8         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Increased uptake of early initiation of antiretroviral therapy and baseline drug resistance testing in San Francisco between 2001 and 2015. <i>PLoS ONE</i> , 2019, 14, e0213167.   | 1.1 | 4         |
| 20 | Response to: Acceptability and Feasibility of a Pharmacist-Led HIV Pre-exposure Prophylaxis Program in the Midwestern United States. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz497.   | 0.4 | 4         |
| 21 | HPTN 067/ADAPT: Correlates of Sex-Related Pre-exposure Prophylaxis Adherence, Thai Men Who Have Sex With Men, and Transgender Women, 2012–2013. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, e18-e26.   | 0.9 | 10        |
| 22 | Baseline Characteristics Explain Differences in Effectiveness of Randomization to Daily Oral TDF/FTC PrEP Between Transgender Women and Cisgender Men Who Have Sex With Men in the iPrEx Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, e94-e98. | 0.9 | 13        |
| 23 | Adherence to PrEP Among Young Men Who Have Sex With Men Participating in a Sexual Health Services Demonstration Project in Alameda County, California. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, 406-413.  | 0.9 | 11        |
| 24 | Factors Associated With Sex-Related Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men in New York City in HPTN 067. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 80, 551-558.  | 0.9 | 24        |
| 25 | Brief Report: Cocaine Use and Pre-exposure Prophylaxis: Adherence, Care Engagement, and Kidney Function. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, 78-82.  | 0.9 | 18        |
| 26 | Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, 149-158.  | 0.9 | 12        |
| 27 | Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, 34-40.   | 0.9 | 5         |
| 28 | Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. <i>Lancet HIV</i> , 2019, 6, e43-e50.  | 2.1 | 43        |
| 29 | Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project. <i>Aids</i> , 2019, 33, 867-872.  | 1.0 | 29        |
| 30 | Skating on thin ice: stimulant use and suboptimal adherence to HIV pre-exposure prophylaxis. <i>Journal of the International AIDS Society</i> , 2018, 21, e25103.   | 1.2 | 53        |
| 31 | A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis. <i>AIDS Patient Care and STDs</i> , 2018, 32, 104-111.   | 1.1 | 68        |
| 32 | Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. <i>Clinical Infectious Diseases</i> , 2018, 67, 411-419.  | 2.9 | 50        |
| 33 | Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 1712-1721.  | 2.9 | 48        |
| 34 | In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs?. <i>Aids</i> , 2018, 32, 809-818.  | 1.0 | 13        |
| 35 | Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States. <i>AIDS and Behavior</i> , 2018, 22, 3540-3549.  | 1.4 | 39        |
| 36 | Performance of the BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection. <i>Journal of Clinical Virology</i> , 2018, 99-100, 67-70.   | 1.6 | 7         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. <i>Journal of Psychopharmacology</i> , 2018, 32, 779-792.       | 2.0 | 84        |
| 38 | Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. <i>Lancet HIV</i> , 2018, 5, e68-e78.  | 2.1 | 96        |
| 39 | HIV sero disclosure among men who have sex with men and transgender women on HIV pre-exposure prophylaxis. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 466-472.                          | 0.6 | 4         |
| 40 | Sex, PrEP, and Stigma: Experiences with HIV Pre-exposure Prophylaxis Among New York City MSM Participating in the HPTN 067/ADAPT Study. <i>AIDS and Behavior</i> , 2018, 22, 1139-1149.   | 1.4 | 76        |
| 41 | Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. <i>HIV Clinical Trials</i> , 2018, 19, 129-138.                             | 2.0 | 51        |
| 42 | Repeated False-Positive HIV Test Results in a Patient Taking HIV Pre-Exposure Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy197.   | 0.4 | 12        |
| 43 | “Losing the Phobia”: Understanding How HIV Pre-exposure Prophylaxis Facilitates Bridging the Serodivide Among Men Who Have Sex With Men. <i>Frontiers in Public Health</i> , 2018, 6, 250.                                      | 1.3 | 25        |
| 44 | Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 169-174.      | 0.9 | 20        |
| 45 | The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2018, 22, 3673-3680.  | 1.4 | 33        |
| 46 | Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067. <i>PLoS ONE</i> , 2018, 13, e0195764.   | 1.1 | 12        |
| 47 | Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2018, 67, 962-964.  | 2.9 | 35        |
| 48 | Protocol for an HIV Pre-exposure Prophylaxis (PrEP) Population Level Intervention Study in Victoria Australia: The PrEPX Study. <i>Frontiers in Public Health</i> , 2018, 6, 151.   | 1.3 | 35        |
| 49 | Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial. <i>PLoS ONE</i> , 2018, 13, e0190118.   | 1.1 | 18        |
| 50 | Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework. <i>AIDS and Behavior</i> , 2017, 21, 1361-1375.                                | 1.4 | 109       |
| 51 | Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 778-783.            | 0.5 | 52        |
| 52 | International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic Status. <i>Sexually Transmitted Diseases</i> , 2017, 44, 306-309.   | 0.8 | 0         |
| 53 | Response to: A double-edged sword: does highly active antiretroviral therapy contribute to syphilis incidence by impairing immunity to <i>Treponema pallidum</i> ?. <i>Sexually Transmitted Infections</i> , 2017, 93, 313-313. | 0.8 | 1         |
| 54 | Risk, safety and sex among male PrEP users: time for a new understanding. <i>Culture, Health and Sexuality</i> , 2017, 19, 1301-1313.   | 1.0 | 75        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 75, 271-279.  | 0.9 | 40        |
| 56 | Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users. <i>Aids</i> , 2017, 31, 1709-1714.   | 1.0 | 103       |
| 57 | Is pericoital or peri-insemination preexposure prophylaxis effective human immunodeficiency prevention for vaginal exposures?. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 230-231.                          | 0.7 | 0         |
| 58 | Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. <i>Lancet HIV</i> , 2017, 4, e331-e340.                | 2.1 | 187       |
| 59 | Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature. <i>AIDS and Behavior</i> , 2017, 21, 1325-1335.                    | 1.4 | 151       |
| 60 | Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, e104-e106.                                      | 0.9 | 64        |
| 61 | Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, 177-182.                            | 0.9 | 25        |
| 62 | Recent advances in pre-exposure prophylaxis for HIV. <i>BMJ: British Medical Journal</i> , 2017, 359, j5011.   | 2.4 | 101       |
| 63 | HIV-1 Drug Resistance in Pre-exposure Prophylaxis Trials. , 2017, , 479-498.   |     | 0         |
| 64 | The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. <i>Journal of the International AIDS Society</i> , 2016, 19, 21105.  | 1.2 | 115       |
| 65 | The Safety of Tenofovir+Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 281-286.                            | 0.9 | 25        |
| 66 | What people want from sex and preexposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 3-9.   | 1.5 | 66        |
| 67 | Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, e115-e118.  | 0.9 | 29        |
| 68 | Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 72, 184-188.  | 0.9 | 1         |
| 69 | HIV moments and pre-exposure prophylaxis. <i>Lancet, The</i> , 2016, 387, 1507-1508.   | 6.3 | 11        |
| 70 | PrEP adherence among trans women in Brazil—access needed for this key population — Authors' reply. <i>Lancet HIV</i> , 2016, 3, e200-e201.   | 2.1 | 1         |
| 71 | Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. <i>Aids</i> , 2016, 30, 1973-1983.   | 1.0 | 721       |
| 72 | The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study. <i>AIDS and Behavior</i> , 2016, 20, 1527-1534. | 1.4 | 41        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Pharmacology supports on-demand PrEP. <i>Lancet HIV,the</i> , 2016, 3, e405-e406.   | 2.1 | 17        |
| 74 | Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. <i>Lancet HIV,the</i> , 2016, 3, e521-e528. | 2.1 | 66        |
| 75 | Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6692-6697.   | 1.4 | 59        |
| 76 | HIV Serodisclosure and Sexual Behavior During International Travel. <i>Sexually Transmitted Diseases</i> , 2016, 43, 459-464.   | 0.8 | 9         |
| 77 | Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, S226-S229.  | 0.9 | 33        |
| 78 | Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study. <i>AIDS and Behavior</i> , 2016, 20, 1535-1540.  | 1.4 | 33        |
| 79 | Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. <i>Clinical Infectious Diseases</i> , 2016, 62, 1172-1177.  | 2.9 | 40        |
| 80 | Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. <i>JAMA Internal Medicine</i> , 2016, 176, 75.   | 2.6 | 535       |
| 81 | Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW). <i>AIDS and Behavior</i> , 2016, 20, 1478-1488.  | 1.4 | 38        |
| 82 | Persistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+T-Cell Activation. <i>Journal of Infectious Diseases</i> , 2016, 213, 569-573.   | 1.9 | 11        |
| 83 | Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 606-609.  | 0.9 | 9         |
| 84 | Antiretroviral pre-exposure prophylaxis implementation in the United States: a work in progress. <i>Journal of the International AIDS Society</i> , 2015, 18, 19980.  | 1.2 | 53        |
| 85 | Transactional sex and prevalence of STIs: a cross-sectional study of MSM and transwomen screened for an HIV prevention trial. <i>International Journal of STD and AIDS</i> , 2015, 26, 879-886.                     | 0.5 | 29        |
| 86 | HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. <i>Lancet HIV,the</i> , 2015, 2, e512-e519.  | 2.1 | 225       |
| 87 | <i>Editorial Commentary</i> : Keeping Our Eyes on the Prize: No New HIV Infections With Increased Use of HIV Pre-exposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2015, 61, 1604-1605.                   | 2.9 | 15        |
| 88 | Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2015, 61, 572-580.                | 2.9 | 132       |
| 89 | The FACTS about women and pre-exposure prophylaxis. <i>Lancet HIV,the</i> , 2015, 2, e228.  | 2.1 | 3         |
| 90 | Ending Sexual HIV Transmission: Lessons Learned from Perinatal HIV. <i>Journal of the Association of Nurses in AIDS Care</i> , 2015, 26, 520-525.   | 0.4 | 3         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. <i>Journal of Infectious Diseases</i> , 2015, 212, 1402-1406. | 1.9 | 62        |
| 92  | Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8379-8384.   | 3.3 | 14        |
| 93  | Weighing the Risk of Drug Resistance With the Benefits of HIV Preexposure Prophylaxis. <i>Journal of Infectious Diseases</i> , 2015, 211, 1202-4.   | 1.9 | 15        |
| 94  | Streamlining HIV Testing for HIV Preexposure Prophylaxis. <i>Journal of Clinical Microbiology</i> , 2015, 53, 179-183.  | 1.8 | 10        |
| 95  | Gay and bisexual men engage in fewer risky sexual behaviors while traveling internationally: a cross-sectional study in San Francisco. <i>Sexually Transmitted Infections</i> , 2015, 91, 220-225.  | 0.8 | 16        |
| 96  | Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. <i>Aids</i> , 2015, 29, 331-337.  | 1.0 | 37        |
| 97  | Acceptability of drug detection monitoring among participants in an open-label pre-exposure prophylaxis study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2015, 27, 1199-1204.  | 0.6 | 27        |
| 98  | Integrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early Treatment. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv126.   | 0.4 | 9         |
| 99  | Reply to Boyd et al. <i>Clinical Infectious Diseases</i> , 2015, 60, 327-327.   | 2.9 | 0         |
| 100 | Strong Relationship between Oral Dose and Tenofovir Hair Levels in a Randomized Trial: Hair as a Potential Adherence Measure for Pre-Exposure Prophylaxis (PrEP). <i>PLoS ONE</i> , 2014, 9, e83736.  | 1.1 | 125       |
| 101 | HIV-1 Drug Resistance in Preexposure Prophylaxis Trials. , 2014, , 1-18.  |     | 0         |
| 102 | Helping our patients take <scp>HIV</scp> preâ€œexposure prophylaxis (<scp>PrEP</scp>): a systematic review of adherence interventions. <i>HIV Medicine</i> , 2014, 15, 385-395.   | 1.0 | 52        |
| 103 | Regulatory Considerations for Antiretroviral Prophylaxis to Prevent HIV Acquisition. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 153-155.   | 2.3 | 2         |
| 104 | Integrated Next Step Counseling for Sexual Health Promotion and Medication Adherence for Individuals Using Pre-exposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A159-A159.   | 0.5 | 4         |
| 105 | Syphilis Predicts HIV Incidence Among Men and Transgender Women Who Have Sex With Men in a Preexposure Prophylaxis Trial. <i>Clinical Infectious Diseases</i> , 2014, 59, 1020-1026.  | 2.9 | 132       |
| 106 | Patterns and Correlates of PrEP Drug Detection Among MSM and Transgender Women in the Global iPrEx Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 528-537.  | 0.9 | 63        |
| 107 | Study Product Adherence Measurement in the iPrEx Placebo-Controlled Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 530-537.   | 0.9 | 73        |
| 108 | HIV Prevention in Clinical Care Settings. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 390.   | 3.8 | 109       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 109 | HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 468-475.                                 | 4.6  | 128       |
| 110 | Reasons Boston MSM Enrolled in Placebo Controlled PrEP Trials Did Not Continue Using PrEP When it Was Available in an Open Label Study. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A28-A29.   | 0.5  | 0         |
| 111 | Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 820-829.  | 4.6  | 1,039     |
| 112 | HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial. <i>Journal of Infectious Diseases</i> , 2014, 210, 1217-1227.  | 1.9  | 68        |
| 113 | Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. <i>Aids</i> , 2014, 28, 851-859.  | 1.0  | 123       |
| 114 | Daily Oral Emtricitabine/Tenofovir Preexposure Prophylaxis and Herpes Simplex Virus Type 2 among Men Who Have Sex with Men. <i>PLoS ONE</i> , 2014, 9, e91513.   | 1.1  | 27        |
| 115 | Fluorescence-linked Antigen Quantification (FLAQ) Assay for Fast Quantification of HIV-1 p24Gag. <i>Bio-protocol</i> , 2014, 4, .  | 0.2  | 8         |
| 116 | Use of Antiretrovirals for HIV Prevention: What Do We Know and What Donâ€™t We Know?. <i>Current HIV/AIDS Reports</i> , 2013, 10, 142-151.   | 1.1  | 60        |
| 117 | Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013, 25, 961-967. | 0.6  | 91        |
| 118 | Participant Experiences and Facilitators and Barriers to Pill Use Among Men Who Have Sex with Men in the iPrEx Pre-Exposure Prophylaxis Trial in San Francisco. <i>AIDS Patient Care and STDs</i> , 2013, 27, 560-566.                               | 1.1  | 76        |
| 119 | Randomized Trial of Clinical Safety of Daily Oral Tenofovir Disoproxil Fumarate Among HIV-Uninfected Men Who Have Sex With Men in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 79-86.                | 0.9  | 158       |
| 120 | Changes in Seroadaptive Practices from before to after Diagnosis of Recent HIV Infection among Men Who Have Sex with Men. <i>PLoS ONE</i> , 2013, 8, e55397.   | 1.1  | 33        |
| 121 | No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis. <i>PLoS ONE</i> , 2013, 8, e81997.   | 1.1  | 193       |
| 122 | Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men. <i>Science Translational Medicine</i> , 2012, 4, 151ra125.  | 5.8  | 807       |
| 123 | The Potential Impact of Pre-Exposure Prophylaxis for HIV Prevention among Men Who Have Sex with Men and Transwomen in Lima, Peru: A Mathematical Modelling Study. <i>PLoS Medicine</i> , 2012, 9, e1001323.  | 3.9  | 76        |
| 124 | Preexposure Prophylaxis for HIV Infection among African Women. <i>New England Journal of Medicine</i> , 2012, 367, 411-422.  | 13.9 | 1,377     |
| 125 | Supporting Study Product Use and Accuracy in Self-Report in the iPrEx Study: Next Step Counseling and Neutral Assessment. <i>AIDS and Behavior</i> , 2012, 16, 1243-1259.  | 1.4  | 71        |
| 126 | Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco. <i>PLoS ONE</i> , 2011, 6, e23688.  | 1.1  | 144       |



| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 127 | Sentinel Surveillance of HIV-1 Transmitted Drug Resistance, Acute Infection and Recent Infection. PLoS ONE, 2011, 6, e25281.  | 1.1  | 41        |
| 128 | Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. Journal of Antimicrobial Chemotherapy, 2011, 66, 240-250.  | 1.3  | 159       |
| 129 | Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation Classes. Journal of Infectious Diseases, 2011, 203, 1174-1181.   | 1.9  | 125       |
| 130 | HIV RNA level in early infection is predicted by viral load in the transmission source. Aids, 2010, 24, 941-945.  | 1.0  | 65        |
| 131 | Sexual risk behaviours and HIV-1 prevalence among urban men who have sex with men in Cape Town, South Africa. Sexual Health, 2010, 7, 149.  | 0.4  | 53        |
| 132 | Transmitted Drug Resistance in Persons with Acute/Early HIV-1 in San Francisco, 2002-2009. PLoS ONE, 2010, 5, e15510.   | 1.1  | 64        |
| 133 | Antiretroviral Agents Used by HIV-Uninfected Persons for Prevention: Pre- and Postexposure Prophylaxis. Clinical Infectious Diseases, 2010, 50, S96-S101.   | 2.9  | 48        |
| 134 | Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. New England Journal of Medicine, 2010, 363, 2587-2599.  | 13.9 | 4,268     |
| 135 | Sexual Seroadaptation: Lessons for Prevention and Sex Research from a Cohort of HIV-Positive Men Who Have Sex with Men. PLoS ONE, 2010, 5, e8831.   | 1.1  | 42        |
| 136 | Frequent International Travel by Men Who Have Sex With Men Recently Diagnosed With HIV-1: Potential for Transmission of Primary HIV-1 Drug Resistance: Table 1. Journal of Travel Medicine, 2008, 15, 454-456.                                      | 1.4  | 18        |
| 137 | Potentially Exposed but Uninfected Individuals Produce Cytotoxic and Polyfunctional Human Immunodeficiency Virus Type 1-Specific CD8 <sup>+</sup> T-Cell Responses Which Can Be Defined to the Epitope Level. Vaccine Journal, 2008, 15, 1745-1748. | 3.2  | 30        |
| 138 | Whither or Wither Microbicides?. Science, 2008, 321, 532-534.   | 6.0  | 126       |
| 139 | Immunity to HIV-1 Is Influenced by Continued Natural Exposure to Exogenous Virus. PLoS Pathogens, 2008, 4, e1000185.  | 2.1  | 14        |
| 140 | Distinct Patterns of Cytokine Regulation of APOBEC3G Expression and Activity in Primary Lymphocytes, Macrophages, and Dendritic Cells. Journal of Biological Chemistry, 2007, 282, 3539-3546.   | 1.6  | 134       |
| 141 | Target Cell APOBEC3C Can Induce Limited G-to-A Mutation in HIV-1. PLoS Pathogens, 2007, 3, e153.  | 2.1  | 51        |
| 142 | Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial. PLOS Clinical Trials, 2007, 2, e27.  | 3.5  | 233       |
| 143 | Reply to McGovern. Clinical Infectious Diseases, 2007, 44, 1013-1013.   | 2.9  | 0         |
| 144 | Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance. Aids, 2007, 21, 239-241.   | 1.0  | 46        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | Dehydroepiandrosterone (DHEA) Effects on HIV Replication and Host Immunity: A Randomized Placebo-Controlled Study. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 77-85.   | 0.5 | 25        |
| 146 | Research in situ. <i>Nature Methods</i> , 2007, 4, 887-890.   | 9.0 | 4         |
| 147 | HIV Drug-resistant Strains as Epidemiologic Sentinels. <i>Emerging Infectious Diseases</i> , 2006, 12, 191-197.   | 2.0 | 13        |
| 148 | Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity. <i>Aids</i> , 2006, 20, 2123-2125.  | 1.0 | 42        |
| 149 | Linking HIV and Antiretroviral Drug Resistance Surveillance in Peru. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 501-505.   | 0.9 | 47        |
| 150 | Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. <i>Aids</i> , 2006, 20, 2193-2197.   | 1.0 | 66        |
| 151 | HIV-1-Specific CD4+ T Cell Responses in Chronically HIV-1 Infected Blippers on Antiretroviral Therapy in Relation to Viral Replication Following Treatment Interruption. <i>Journal of Clinical Immunology</i> , 2006, 26, 40-54.                                     | 2.0 | 19        |
| 152 | Genotypic Resistance and Immunologic Outcomes Among HIV-1-Infected Women With Viral Failure. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 41, 68-74.   | 0.9 | 10        |
| 153 | The Cost of Access to HIV Treatment. <i>Science</i> , 2006, 314, 1540-1541.   | 6.0 | 0         |
| 154 | Chemoprophylaxis of HIV Infection: Moving Forward with Caution. <i>Journal of Infectious Diseases</i> , 2006, 194, 874-876.   | 1.9 | 19        |
| 155 | HIV/AIDS: Antiretroviral Therapy for Hepatitis B Virusâ€“HIVâ€“Coinfected Patients: Promises and Pitfalls. <i>Clinical Infectious Diseases</i> , 2006, 43, 904-910.   | 2.9 | 67        |
| 156 | Preexposure Prophylaxis for HIV. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 863.  | 3.8 | 66        |
| 157 | Human Immunodeficiency Virus Type 1 Vpr Induces DNA Replication Stress In Vitro and In Vivo. <i>Journal of Virology</i> , 2006, 80, 10407-10418.  | 1.5 | 91        |
| 158 | Increases in sexually transmitted infections and sexual risk behaviour without a concurrent increase in HIV incidence among men who have sex with men in San Francisco: a suggestion of HIV serosorting?. <i>Sexually Transmitted Infections</i> , 2006, 82, 461-466. | 0.8 | 196       |
| 159 | T-Cell Activation and Memory Phenotypes in Cerebrospinal Fluid During HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 16-22.   | 0.9 | 29        |
| 160 | High-Risk Sexual Behavior in Adults With Genotypically Proven Antiretroviral-Resistant HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 463-471.  | 0.9 | 36        |
| 161 | Enrichment of activated monocytes in cerebrospinal fluid during antiretroviral therapy. <i>Aids</i> , 2005, 19, 1351-1359.  | 1.0 | 16        |
| 162 | A decrease in drug resistance levels of the HIV epidemic can be bad news. <i>Bulletin of Mathematical Biology</i> , 2005, 67, 761-782.  | 0.9 | 13        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 163 | The role of viral fitness in HIV pathogenesis. <i>Current HIV/AIDS Reports</i> , 2005, 2, 29-34.  | 1.1  | 16        |
| 164 | AIDS: Promote HIV Chemoprophylaxis Research, Don't Prevent It. <i>Science</i> , 2005, 309, 2170-2171.   | 6.0  | 67        |
| 165 | Resistance Testing in Drug-Naive HIV-Infected Patients: Is it Time?. <i>Clinical Infectious Diseases</i> , 2005, 41, 1324-1325.   | 2.9  | 35        |
| 166 | Detection of Acute HIV Infections. <i>New England Journal of Medicine</i> , 2005, 353, 631-633.   | 13.9 | 32        |
| 167 | Interruption of Treatment with Individual Therapeutic Drug Classes in Adults with Multidrug-Resistant HIV Infection. <i>Journal of Infectious Diseases</i> , 2005, 192, 1537-1544.              | 1.9  | 146       |
| 168 | Seroconversion Following Nonoccupational Postexposure Prophylaxis against HIV. <i>Clinical Infectious Diseases</i> , 2005, 41, 1507-1513.   | 2.9  | 134       |
| 169 | Higher CD4+T Cell Counts Associated with Low Viral Replication Capacity among Treatment-Naive Adults in Early HIV Infection. <i>Journal of Infectious Diseases</i> , 2004, 190, 251-256.        | 1.9  | 74        |
| 170 | Human Immunodeficiency Virus Type 1 Superinfection Was Not Detected following 215 Years of Injection Drug User Exposure. <i>Journal of Virology</i> , 2004, 78, 94-103.                         | 1.5  | 75        |
| 171 | Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. <i>Aids</i> , 2004, 18, 81-88.   | 1.0  | 244       |
| 172 | HIV-1 superinfection and viral diversity. <i>Aids</i> , 2004, 18, 1513-1520.  | 1.0  | 29        |
| 173 | Virological evaluation of the "Ottawa case"™ indicates no evidence for HIV-1 superinfection. <i>Aids</i> , 2004, 18, 331-334.   | 1.0  | 9         |
| 174 | Randomized, Controlled Trial of Therapy Interruption in Chronic HIV-1 Infection. <i>PLoS Medicine</i> , 2004, 1, e64.   | 3.9  | 67        |
| 175 | The clinical implications of reduced viral fitness. <i>Current Infectious Disease Reports</i> , 2004, 6, 151-158.   | 1.3  | 9         |
| 176 | Relating HIV-1 Sequence Variation to Replication Capacity via Trees and Forests. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2004, 3, 1-18.                             | 0.2  | 35        |
| 177 | Persistence of primary drug resistance among recently HIV-1 infected adults. <i>Aids</i> , 2004, 18, 1683-1689.   | 1.0  | 139       |
| 178 | HIV-Producing T Cells in Cerebrospinal Fluid. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 37, 1237-1244.  | 0.9  | 13        |
| 179 | Absence of HBV and HCV, HTLV-I and -II, and human herpes virus-8 activation after allogeneic RBC transfusion in patients with advanced HIV-1 infection. <i>Transfusion</i> , 2003, 43, 451-458. | 0.8  | 11        |
| 180 | Performance Characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1594-1599.                          | 1.8  | 71        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 181 | Accuracy of the TRUGENE HIV-1 Genotyping Kit. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1586-1593.   | 1.8  | 111       |
| 182 | Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients. <i>Aids</i> , 2003, 17, 2337-2343.  | 1.0  | 23        |
| 183 | Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. <i>Aids</i> , 2003, 17, 361-370.   | 1.0  | 80        |
| 184 | High levels of adherence do not prevent accumulation of HIV drug resistance mutations. <i>Aids</i> , 2003, 17, 1925-1932.  | 1.0  | 200       |
| 185 | Increased Human T-Lymphotropic Virus Type II Proviral Load Following Highly Active Retroviral Therapy in HIV-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 655-656.                             | 0.9  | 18        |
| 186 | Dual Pressure from Antiretroviral Therapy and Cell-Mediated Immune Response on the Human Immunodeficiency Virus Type 1 Protease Gene. <i>Journal of Virology</i> , 2003, 77, 6743-6752.  | 1.5  | 46        |
| 187 | Real-time quantitation of HIV-1 p24 and SIV p27 using fluorescence-linked antigen quantification assays. <i>Aids</i> , 2003, 17, 629-631.  | 1.0  | 9         |
| 188 | Drug resistance mutations in HIV-1. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2003, 11, 92-6.  | 2.9  | 35        |
| 189 | Evolution of Phenotypic Drug Susceptibility and Viral Replication Capacity during Long-Term Virologic Failure of Protease Inhibitor Therapy in Human Immunodeficiency Virus-Infected Adults. <i>Journal of Virology</i> , 2002, 76, 11104-11112. | 1.5  | 151       |
| 190 | Selective Loss of Innate CD4+ VÎ±24 Natural Killer T Cells in Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2002, 76, 7528-7534.  | 1.5  | 152       |
| 191 | Time Trends in Primary HIV-1 Drug Resistance Among Recently Infected Persons. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 181.  | 3.8  | 416       |
| 192 | Progress Toward a Human CD4/CCR5 Transgenic Rat Model for De Novo Infection by Human Immunodeficiency Virus Type 1. <i>Journal of Experimental Medicine</i> , 2002, 195, 719-736.  | 4.2  | 97        |
| 193 | CD4+T Cell Kinetics and Activation in Human Immunodeficiency Virus-Infected Patients Who Remain Viremic Despite Long-Term Treatment with Protease Inhibitor-Based Therapy. <i>Journal of Infectious Diseases</i> , 2002, 185, 315-323.           | 1.9  | 103       |
| 194 | HIV-Related Neuropathology, 1985 to 1999: Rising Prevalence of HIV Encephalopathy in the Era of Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 31, 171-177.                         | 0.9  | 206       |
| 195 | Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. <i>Aids</i> , 2002, 16, 1103-1111.   | 1.0  | 140       |
| 196 | Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. <i>Aids</i> , 2002, 16, 201-207.   | 1.0  | 150       |
| 197 | Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. <i>Aids</i> , 2002, 16, 2342-2344.   | 1.0  | 47        |
| 198 | Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable Viremia. <i>New England Journal of Medicine</i> , 2001, 344, 472-480.                                   | 13.9 | 672       |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 199 | Protease inhibitor-resistant HIV-1 from patients with preserved CD4 cell counts is cytopathic in activated CD4 T lymphocytes. <i>Aids</i> , 2001, 15, 179-184.  | 1.0  | 11        |
| 200 | Cerebrospinal fluid response to structured treatment interruption after virological failure. <i>Aids</i> , 2001, 15, 1251-1259.   | 1.0  | 59        |
| 201 | Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. <i>Nature Medicine</i> , 2001, 7, 73-79.   | 15.2 | 498       |
| 202 | Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. <i>Nature Medicine</i> , 2001, 7, 712-718.  | 15.2 | 141       |
| 203 | Primary and Recombinant HIV Type 1 Strains Resistant to Protease Inhibitors Are Pathogenic in Mature Human Lymphoid Tissues. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 517-523.   | 0.5  | 20        |
| 204 | Postexposure Prophylaxis for Human Immunodeficiency Virus Infection after Sexual or Injection Drug Use Exposure: Identification and Characterization of the Source of Exposure. <i>Journal of Infectious Diseases</i> , 2001, 184, 1608-1612. | 1.9  | 28        |
| 205 | Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. <i>Aids</i> , 2000, 14, 2877-2887.   | 1.0  | 49        |
| 206 | Reversal of Human Immunodeficiency Virus Type 1-Associated Hematosuppression by Effective Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2000, 30, 504-510.  | 2.9  | 57        |
| 207 | Cytopathicity of Human Immunodeficiency Virus Type 2 (HIV-2) in Human Lymphoid Tissue Is Coreceptor Dependent and Comparable to That of HIV-1. <i>Journal of Virology</i> , 2000, 74, 9594-9600.  | 1.5  | 54        |
| 208 | A Tale of Two Futures: HIV and Antiretroviral Therapy in San Francisco. <i>Science</i> , 2000, 287, 650-654.  | 6.0  | 349       |
| 209 | HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. <i>Aids</i> , 1999, 13, F35-F43.   | 1.0  | 382       |
| 210 | Short Communication Antibody and Cellular Immune Responses in Breakthrough Infection Subjects after HIV Type 1 Glycoprotein 120 Vaccination. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1685-1689.                               | 0.5  | 25        |
| 211 | Evolution of viral quasispecies in interferon-treated patients with chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 1999, 31, 618-627.  | 1.8  | 11        |
| 212 | Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. <i>Aids</i> , 1999, 13, 1051-1061.   | 1.0  | 118       |
| 213 | Not all is dead in HIV-1 graveyard. <i>Lancet, The</i> , 1998, 351, 308-309.  | 6.3  | 6         |
| 214 | Sexual Transmission of an HIV-1 Variant Resistant to Multiple Reverse-Transcriptase and Protease Inhibitors. <i>New England Journal of Medicine</i> , 1998, 339, 307-311.   | 13.9 | 456       |
| 215 | Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. <i>Aids</i> , 1998, 12, F97-F102.   | 1.0  | 90        |
| 216 | Diverse Host Responses and Outcomes following Simian Immunodeficiency Virus SIVmac239 Infection in Sooty Mangabeys and Rhesus Macaques. <i>Journal of Virology</i> , 1998, 72, 9597-9611.   | 1.5  | 138       |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 217 | High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection.. Journal of Clinical Investigation, 1998, 101, 2301-2308.                       | 3.9  | 245       |
| 218 | HIV replication and pathogenesis. Current Opinion in Infectious Diseases, 1996, 9, 7-13.  | 1.3  | 2         |
| 219 | Frequent Presence of a Novel Herpesvirus Genome in Lesions of Human Immunodeficiency Virus-Negative Kaposi's Sarcoma. Journal of Infectious Diseases, 1996, 173, 248-251. | 1.9  | 83        |
| 220 | The High Prevalence of Genital Herpes Among Patients With Genital Ulcer Disease in Uganda. Sexually Transmitted Diseases, 1995, 22, 351-354.                              | 0.8  | 32        |
| 221 | Activation of virus replication after vaccination of HIV-1-infected individuals.. Journal of Experimental Medicine, 1995, 182, 1727-1737.                                 | 4.2  | 332       |
| 222 | Early Christian Geography. Vigiliae Christianae, 1992, 46, 105-111.   | 0.1  | 3         |
| 223 | Acyclovir-Resistant Herpes Simplex Virus Infections in Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1989, 320, 293-296.         | 13.9 | 470       |
| 224 | Five Apologists and Marcus Aurelius. Vigiliae Christianae, 1988, 42, 1-17.  | 0.1  | 41        |
| 225 | The Apostolic Fathers' First Thousand Years. Church History, 1988, 57, 20-28.   | 0.0  | 0         |